|
G
|
Abcb11
|
ATP binding cassette subfamily B member 11
|
decreases activity
|
ISO
|
lapatinib results in decreased activity of ABCB11 protein
|
CTD |
PMID:20829430 PMID:23956101 PMID:28437613 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
multiple interactions
|
ISO
|
lapatinib inhibits the reaction [ABCB1 protein results in increased export of and results in decreased susceptibility to Doxorubicin]; lapatinib inhibits the reaction [azidoprazosin binds to ABCB1 protein]; lapatinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]
|
CTD |
PMID:18829547 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
G
|
Abcb4
|
ATP binding cassette subfamily B member 4
|
decreases activity
|
ISO
|
lapatinib results in decreased activity of ABCB4 protein
|
CTD |
PMID:28437613 |
|
NCBI chr 4:26,106,895...26,164,440
|
|
G
|
Abcg2
|
ATP binding cassette subfamily G member 2
|
multiple interactions
|
ISO
|
lapatinib inhibits the reaction [ABCG2 gene mutant form results in increased export of and results in decreased susceptibility to Mitoxantrone]; lapatinib inhibits the reaction [ABCG2 protein results in decreased susceptibility to Topotecan]; lapatinib inhibits the reaction [ABCG2 protein results in increased export of and results in decreased susceptibility to Mitoxantrone]; lapatinib inhibits the reaction [ABCG2 protein results in increased export of Methotrexate]; lapatinib inhibits the reaction [ABCG2 protein results in increased transport of estradiol-17 beta-glucuronide]; lapatinib inhibits the reaction [azidoprazosin binds to ABCG2 protein]; lapatinib promotes the reaction [ABCG2 protein results in increased hydrolysis of Adenosine Triphosphate]
|
CTD |
PMID:18829547 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493
|
|
G
|
Acta2
|
actin alpha 2, smooth muscle
|
multiple interactions
|
ISO
|
[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of ACTA2 protein; Niclosamide inhibits the reaction [[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of ACTA2 protein]
|
CTD |
PMID:26643609 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions decreases expression decreases activity decreases phosphorylation
|
ISO
|
[Bortezomib co-treated with Lapatinib] results in decreased phosphorylation of AKT1 protein; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of AKT1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of AKT1 protein] lapatinib results in decreased expression of AKT1 protein; lapatinib results in decreased expression of AKT1 protein modified form lapatinib results in decreased activity of AKT1 protein Lapatinib results in decreased phosphorylation of AKT1 protein
|
CTD |
PMID:15665275 PMID:16091755 PMID:19435893 PMID:19509167 PMID:20701607 PMID:29387217 PMID:32890875 PMID:33396024 More...
|
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Aldh1a1
|
aldehyde dehydrogenase 1 family, member A1
|
multiple interactions
|
ISO
|
[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of ALDH1A1 protein
|
CTD |
PMID:26643609 |
|
NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
increases expression multiple interactions
|
ISO
|
Lapatinib results in increased expression of BAX protein 2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased expression of BAX protein]; Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of BAX protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of BAX protein]]
|
CTD |
PMID:29387217 PMID:32890875 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
decreases expression multiple interactions
|
ISO
|
Lapatinib results in decreased expression of BCL2 protein AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of BCL2 protein]]; AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]]
|
CTD |
PMID:29387217 PMID:32890875 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Birc5
|
baculoviral IAP repeat-containing 5
|
decreases expression
|
ISO
|
lapatinib results in decreased expression of BIRC5 protein
|
CTD |
PMID:16091755 |
|
NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155
|
|
G
|
Bnip3
|
BCL2 interacting protein 3
|
multiple interactions
|
ISO
|
Lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; Lapatinib inhibits the reaction [concanamycin A results in increased expression of BNIP3 mRNA]
|
CTD |
PMID:25981168 |
|
NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:203,137,778...203,154,962
|
|
G
|
Casp3
|
caspase 3
|
increases cleavage multiple interactions increases activity
|
ISO
|
Lapatinib results in increased cleavage of CASP3 protein 2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased cleavage of CASP3 protein]; AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]] Lapatinib results in increased activity of CASP3 protein
|
CTD |
PMID:29387217 PMID:32890875 PMID:37788138 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp7
|
caspase 7
|
increases activity
|
ISO
|
Lapatinib results in increased activity of CASP7 protein
|
CTD |
PMID:37788138 |
|
NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512
|
|
G
|
Casp9
|
caspase 9
|
multiple interactions increases cleavage increases activity
|
ISO
|
2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased cleavage of CASP9 protein] Lapatinib results in increased activity of CASP9 protein
|
CTD |
PMID:29387217 PMID:37788138 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Ccna2
|
cyclin A2
|
decreases expression
|
ISO
|
lapatinib results in decreased expression of CCNA2 protein
|
CTD |
PMID:25221644 |
|
NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701
|
|
G
|
Ccnd1
|
cyclin D1
|
multiple interactions decreases expression
|
ISO
|
[afimoxifene co-treated with Lapatinib] results in decreased expression of CCND1 protein; [Genistein co-treated with Lapatinib] affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of CCND1 protein]; AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]]; ERBB2 protein affects the reaction [Lapatinib results in decreased expression of CCND1 protein]; Lapatinib affects the reaction [CXCL8 protein affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of CCND1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]] lapatinib results in decreased expression of CCND1 protein
|
CTD |
PMID:15665275 PMID:25221644 PMID:32890875 PMID:33396024 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
G
|
Ccne1
|
cyclin E1
|
multiple interactions
|
ISO
|
[afimoxifene co-treated with lapatinib] promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]; lapatinib promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]
|
CTD |
PMID:15665275 |
|
NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:99,918,674...99,927,822
|
|
G
|
Cd24
|
CD24 molecule
|
multiple interactions
|
ISO
|
[lapatinib results in decreased susceptibility to lapatinib] which results in decreased expression of CD24 protein
|
CTD |
PMID:26643609 |
|
NCBI chr20:48,655,549...48,661,786
Ensembl chr20:48,655,805...48,661,785
|
|
G
|
Cd44
|
CD44 molecule
|
multiple interactions
|
ISO
|
[Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CD44 protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of CD44 protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CD44 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CD44 protein]]
|
CTD |
PMID:26643609 PMID:33396024 |
|
NCBI chr 3:109,610,824...109,699,776
Ensembl chr 3:109,612,054...109,699,424
|
|
G
|
Cdh1
|
cadherin 1
|
multiple interactions
|
ISO
|
[Genistein co-treated with Lapatinib] promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in decreased expression of CDH1 protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of CDH1 protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in decreased expression of CDH1 protein]
|
CTD |
PMID:26643609 PMID:32890875 PMID:33396024 |
|
NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565
|
|
G
|
Cdh2
|
cadherin 2
|
multiple interactions
|
ISO
|
[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of CDH2 protein; Niclosamide inhibits the reaction [[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of CDH2 protein]
|
CTD |
PMID:26643609 |
|
NCBI chr18:8,051,097...8,265,288
Ensembl chr18:8,051,097...8,265,288
|
|
G
|
Cdk2
|
cyclin dependent kinase 2
|
multiple interactions
|
ISO
|
[afimoxifene co-treated with lapatinib] promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]; lapatinib promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]
|
CTD |
PMID:15665275 |
|
NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,714,392...1,721,878
|
|
G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
multiple interactions
|
ISO
|
Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CDKN1A protein]
|
CTD |
PMID:32890875 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
G
|
Cdkn1b
|
cyclin-dependent kinase inhibitor 1B
|
multiple interactions increases expression
|
ISO
|
[afimoxifene co-treated with Lapatinib] promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]; [afimoxifene co-treated with Lapatinib] results in increased expression of CDKN1B protein; Bortezomib promotes the reaction [Lapatinib results in increased expression of CDKN1B protein]; Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of CDKN1B protein]; Lapatinib promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]; Lapatinib promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]] lapatinib results in increased expression of CDKN1B protein
|
CTD |
PMID:15665275 PMID:20701607 PMID:32890875 |
|
NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
decreases activity increases metabolic processing
|
ISO
|
Lapatinib results in decreased activity of CYP1A1 protein CYP1A1 protein results in increased metabolism of Lapatinib
|
CTD |
PMID:33814510 PMID:37788138 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Cyp1b1
|
cytochrome P450, family 1, subfamily b, polypeptide 1
|
decreases activity
|
ISO
|
Lapatinib results in decreased activity of CYP1B1 protein
|
CTD |
PMID:33814510 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
increases metabolic processing multiple interactions
|
ISO
|
CYP3A4 protein results in increased metabolism of Lapatinib [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased activity of NFE2L2 protein; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of HMOX1 mRNA; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of NQO1 mRNA; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of SOD1 mRNA; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of SOD2 mRNA
|
CTD |
PMID:26958860 PMID:33259822 PMID:37788138 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
Cyp3a9
|
cytochrome P450, family 3, subfamily a, polypeptide 9
|
increases metabolic processing multiple interactions
|
ISO
|
CYP3A5 protein results in increased metabolism of Lapatinib [CYP3A5 protein results in increased metabolism of Lapatinib] which results in increased activity of NFE2L2 protein; CYP3A5 protein inhibits the reaction [Lapatinib results in increased expression of H2AX protein]
|
CTD |
PMID:26958860 PMID:37788138 |
|
NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154
|
|
G
|
Egfr
|
epidermal growth factor receptor
|
decreases activity multiple interactions affects response to substance
|
ISO
|
lapatinib results in decreased activity of EGFR protein KRAS protein affects the reaction [EGFR protein affects the susceptibility to lapatinib]; lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]; lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to MAPK12 protein]]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to PTPN3 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]]
|
CTD |
PMID:15665275 PMID:17192538 PMID:19509167 PMID:20549698 PMID:28739874 |
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358
|
|
G
|
Erbb2
|
erb-b2 receptor tyrosine kinase 2
|
multiple interactions decreases activity decreases expression decreases phosphorylation
|
ISO
|
[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of ERBB2 protein; Bortezomib promotes the reaction [Lapatinib results in decreased phosphorylation of ERBB2 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK1 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK3 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased expression of CCND1 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased expression of MCM7 protein]; Lapatinib promotes the reaction [Bortezomib results in decreased phosphorylation of ERBB2 protein] lapatinib results in decreased activity of ERBB2 protein lapatinib results in decreased expression of ERBB2 protein lapatinib results in decreased phosphorylation of ERBB2 protein
|
CTD |
PMID:15665275 PMID:16091755 PMID:17192538 PMID:19509167 PMID:20197467 PMID:20549698 PMID:20701607 PMID:25221644 PMID:26643609 More...
|
|
NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,907,460...83,931,481
|
|
G
|
Erbb3
|
erb-b2 receptor tyrosine kinase 3
|
decreases expression decreases activity
|
ISO
|
lapatinib results in decreased expression of ERBB3 protein modified form lapatinib results in decreased activity of ERBB3 protein
|
CTD |
PMID:19435893 PMID:19509167 |
|
NCBI chr 7:1,579,079...1,600,379
Ensembl chr 7:1,579,816...1,601,120
|
|
G
|
Esr1
|
estrogen receptor 1
|
decreases activity multiple interactions
|
ISO
|
lapatinib results in decreased activity of ESR1 protein [lapatinib co-treated with afimoxifene] results in decreased activity of ESR1 protein
|
CTD |
PMID:15665275 |
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354
|
|
G
|
Gpt
|
glutamic--pyruvic transaminase
|
increases secretion
|
ISO
|
Lapatinib results in increased secretion of GPT protein
|
CTD |
PMID:29655783 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160
|
|
G
|
H2ax
|
H2A.X variant histone
|
increases expression multiple interactions
|
ISO
|
Lapatinib results in increased expression of H2AX protein CYP3A5 protein inhibits the reaction [Lapatinib results in increased expression of H2AX protein]; CYP3A7 protein inhibits the reaction [Lapatinib results in increased expression of H2AX protein]
|
CTD |
PMID:37788138 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079
|
|
G
|
Hif1a
|
hypoxia inducible factor 1 subunit alpha
|
multiple interactions
|
ISO
|
AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]]; Lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of HIF1A protein]; Lapatinib inhibits the reaction [concanamycin A results in increased expression of HIF1A protein]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]]
|
CTD |
PMID:25981168 PMID:32890875 |
|
NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323
|
|
G
|
Hmox1
|
heme oxygenase 1
|
multiple interactions increases expression
|
ISO
|
[CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of HMOX1 mRNA lapatinib metabolite results in increased expression of HMOX1 mRNA
|
CTD |
PMID:26958860 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
G
|
Jak2
|
Janus kinase 2
|
multiple interactions
|
ISO
|
Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of JAK2 protein]
|
CTD |
PMID:32890875 |
|
NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:236,408,662...236,468,762
|
|
G
|
Kras
|
KRAS proto-oncogene, GTPase
|
decreases response to substance multiple interactions
|
ISO
|
KRAS protein results in decreased susceptibility to lapatinib KRAS protein affects the reaction [EGFR protein affects the susceptibility to lapatinib]
|
CTD |
PMID:28739874 |
|
NCBI chr 4:179,916,255...179,949,613
Ensembl chr 4:179,919,802...179,949,320
|
|
G
|
Ldha
|
lactate dehydrogenase A
|
increases secretion
|
ISO
|
Lapatinib results in increased secretion of LDHA protein
|
CTD |
PMID:37660997 |
|
NCBI chr 1:106,508,092...106,517,512
Ensembl chr 1:106,502,182...106,517,521
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions decreases activity decreases expression decreases phosphorylation
|
ISO
|
ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK1 protein]; Lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK1 protein] lapatinib results in decreased activity of MAPK1 protein lapatinib results in decreased expression of MAPK1 protein lapatinib results in decreased phosphorylation of MAPK1 protein
|
CTD |
PMID:16091755 PMID:20701607 PMID:22233293 PMID:25221644 PMID:32890875 PMID:33396024 More...
|
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk12
|
mitogen-activated protein kinase 12
|
multiple interactions
|
ISO
|
lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to MAPK12 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]]
|
CTD |
PMID:28739874 |
|
NCBI chr 7:122,085,647...122,096,307
Ensembl chr 7:122,085,913...122,096,307
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions decreases activity decreases expression decreases phosphorylation
|
ISO
|
ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK3 protein]; Lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK3 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK3 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK3 protein] lapatinib results in decreased activity of MAPK3 protein lapatinib results in decreased expression of MAPK3 protein lapatinib results in decreased phosphorylation of MAPK3 protein
|
CTD |
PMID:16091755 PMID:20701607 PMID:22233293 PMID:25221644 PMID:32890875 PMID:33396024 More...
|
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mcm7
|
minichromosome maintenance complex component 7
|
multiple interactions decreases expression
|
ISO
|
ERBB2 protein affects the reaction [lapatinib results in decreased expression of MCM7 protein]
|
CTD |
PMID:25221644 |
|
NCBI chr12:22,155,921...22,163,320
Ensembl chr12:22,155,921...22,163,771
|
|
G
|
Mtor
|
mechanistic target of rapamycin kinase
|
multiple interactions
|
ISO
|
[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of MTOR protein; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of MTOR protein]
|
CTD |
PMID:26643609 |
|
NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
multiple interactions increases activity
|
ISO
|
[CYP3A4 protein results in increased metabolism of lapatinib] which results in increased activity of NFE2L2 protein; [CYP3A5 protein results in increased metabolism of lapatinib] which results in increased activity of NFE2L2 protein lapatinib metabolite results in increased activity of NFE2L2 protein
|
CTD |
PMID:26958860 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
G
|
Nqo1
|
NAD(P)H quinone dehydrogenase 1
|
multiple interactions increases expression
|
ISO
|
[CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of NQO1 mRNA lapatinib metabolite results in increased expression of NQO1 mRNA
|
CTD |
PMID:26958860 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
multiple interactions increases cleavage
|
ISO
|
2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased cleavage of PARP1 protein]; [Lapatinib co-treated with bafilomycin A] results in increased cleavage of PARP1 protein; [Lapatinib co-treated with concanamycin A] results in increased cleavage of PARP1 protein; AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased cleavage of PARP1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in decreased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased cleavage of PARP1 protein]]
|
CTD |
PMID:25221644 PMID:25981168 PMID:29387217 PMID:32890875 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Pcna
|
proliferating cell nuclear antigen
|
multiple interactions
|
ISO
|
[Genistein co-treated with Lapatinib] affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of PCNA protein]; AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PCNA protein]]; Lapatinib affects the reaction [CXCL8 protein affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of PCNA protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PCNA protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PCNA protein]]
|
CTD |
PMID:32890875 PMID:33396024 |
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions
|
ISO
|
AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PTGS2 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PTGS2 protein]]
|
CTD |
PMID:32890875 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Ptpn3
|
protein tyrosine phosphatase, non-receptor type 3
|
multiple interactions
|
ISO
|
lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to PTPN3 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]]
|
CTD |
PMID:28739874 |
|
NCBI chr 5:76,703,687...76,822,584
Ensembl chr 5:76,703,687...76,860,470
|
|
G
|
Raf1
|
Raf-1 proto-oncogene, serine/threonine kinase
|
multiple interactions
|
ISO
|
Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of RAF1 protein]
|
CTD |
PMID:32890875 |
|
NCBI chr 4:150,352,158...150,412,813
Ensembl chr 4:150,352,160...150,412,813
|
|
G
|
Rb1
|
RB transcriptional corepressor 1
|
multiple interactions
|
ISO
|
Lapatinib inhibits the reaction [sodium arsenite results in decreased phosphorylation of RB1 protein]
|
CTD |
PMID:32890875 |
|
NCBI chr15:54,780,858...54,911,989
Ensembl chr15:54,780,858...54,911,857
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
ISO
|
[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of RELA protein; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of RELA protein]
|
CTD |
PMID:26643609 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Snai1
|
snail family transcriptional repressor 1
|
multiple interactions decreases response to substance
|
ISO
|
[Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of SNAI1 protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of SNAI1 protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of SNAI1 protein] SNAI1 protein results in decreased susceptibility to lapatinib
|
CTD |
PMID:26643609 PMID:32890875 PMID:33396024 |
|
NCBI chr 3:176,667,476...176,671,965
|
|
G
|
Snai2
|
snail family transcriptional repressor 2
|
multiple interactions
|
ISO
|
[Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein]]
|
CTD |
PMID:33396024 |
|
NCBI chr11:99,686,934...99,690,349
Ensembl chr11:99,686,934...99,690,349
|
|
G
|
Sod1
|
superoxide dismutase 1
|
multiple interactions
|
ISO
|
[CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of SOD1 mRNA
|
CTD |
PMID:26958860 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399
|
|
G
|
Sod2
|
superoxide dismutase 2
|
multiple interactions increases expression
|
ISO
|
[CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of SOD2 mRNA lapatinib metabolite results in increased expression of SOD2 mRNA
|
CTD |
PMID:26958860 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168
|
|
G
|
Sox2
|
SRY-box transcription factor 2
|
multiple interactions
|
ISO
|
[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of SOX2 protein
|
CTD |
PMID:26643609 |
|
NCBI chr 2:119,465,131...119,467,542
Ensembl chr 2:119,454,541...119,496,350
|
|
G
|
Src
|
SRC proto-oncogene, non-receptor tyrosine kinase
|
multiple interactions
|
ISO
|
[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of SRC protein; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of SRC protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of SRC protein]
|
CTD |
PMID:26643609 PMID:32890875 |
|
NCBI chr 3:166,511,616...166,559,463
Ensembl chr 3:166,511,985...166,559,462
|
|
G
|
Stat3
|
signal transducer and activator of transcription 3
|
multiple interactions
|
ISO
|
Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of STAT3 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of STAT3 protein]
|
CTD |
PMID:32890875 PMID:33396024 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
decreases response to substance
|
ISO
|
TGFB1 protein results in decreased susceptibility to lapatinib
|
CTD |
PMID:26643609 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Top1
|
DNA topoisomerase I
|
decreases expression
|
ISO
|
Lapatinib results in decreased expression of TOP1 protein
|
CTD |
PMID:37788138 |
|
NCBI chr 3:169,713,195...169,796,330
Ensembl chr 3:169,713,130...169,796,327
|
|
G
|
Top2a
|
DNA topoisomerase II alpha
|
decreases expression
|
ISO
|
Lapatinib results in decreased expression of TOP2A protein
|
CTD |
PMID:37788138 |
|
NCBI chr10:84,441,954...84,473,093
Ensembl chr10:84,441,954...84,473,366
|
|
G
|
Twist1
|
twist family bHLH transcription factor 1
|
multiple interactions
|
ISO
|
Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 protein]]
|
CTD |
PMID:33396024 |
|
NCBI chr 6:56,402,309...56,404,303
Ensembl chr 6:56,398,061...56,404,965
|
|
G
|
Ugt1a2
|
UDP glucuronosyltransferase 1 family, polypeptide A2
|
decreases activity multiple interactions
|
ISO
|
Lapatinib results in decreased activity of UGT1A3 protein [Lapatinib results in decreased activity of UGT1A3 protein] which results in decreased glucuronidation of obeticholic acid; [Lapatinib results in decreased activity of UGT1A3 protein] which results in decreased glucuronidation of Ursodeoxycholic Acid
|
CTD |
PMID:31299240 |
|
NCBI chr 9:96,239,019...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
G
|
Vegfa
|
vascular endothelial growth factor A
|
multiple interactions
|
ISO
|
AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of VEGFA protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of VEGFA protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of VEGFA protein]]
|
CTD |
PMID:32890875 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194
|
|
G
|
Vim
|
vimentin
|
multiple interactions
|
ISO
|
[Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of VIM protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of VIM protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of VIM protein]
|
CTD |
PMID:26643609 PMID:32890875 PMID:33396024 |
|
NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746
|
|